Trials / Completed
CompletedNCT01374113
Safinamide Renal Impairment Trial
An Open-label, Parallel-group, Single Center, Single Oral Dose Trial to Investigate the Pharmacokinetics (PK) of 50 mg Safinamide in Subjects With Moderate and Severe Renal Impairment Compared to Matched Subjects With Normal Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Newron Pharmaceuticals SPA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of the trial is to investigate the pharmacokinetics (behaviour of the compound in the body) of safinamide in subjects with different degrees of renal impairment in comparison to matched subjects with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 50mg safinamide | 50 mg safinamide on Day 1 |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2011-10-01
- First posted
- 2011-06-15
- Last updated
- 2013-03-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01374113. Inclusion in this directory is not an endorsement.